Efficient activation of pathogenic Δphe501 mutation in monocarboxylate transporter 8 by chemical and pharmacological chaperones

Endocrinology (United States)

Volumn 156, Issue 12, 2015, Pages 4720-4730

  Braun, Doreen ^a   Schweizer, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHAPERONE; COMPLEMENTARY DNA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIMETHYL SULFOXIDE; GENISTEIN; LIOTHYRONINE; MONOCARBOXYLATE TRANSPORTER 8; MUTANT PROTEIN; TAUROCHOLIC ACID; TRIMETHYLAMINE OXIDE; 4-PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN; MONOCARBOXYLATE TRANSPORTER; RADIOACTIVE IODINE; SLC16A2 PROTEIN, HUMAN; THYROXINE;

ANIMAL CELL; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; GENE MUTATION; HORMONE TRANSPORT; IC50; MDCK CELL LINE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TRANSPORT; STABLE TRANSFECTION; TEMPERATURE SENSITIVE MUTANT; THYROID HORMONE RELEASE; UREA CYCLE DISORDER; XENOPUS LAEVIS; ANIMAL; CELL MEMBRANE; CONFOCAL MICROSCOPY; DOG; DRUG EFFECTS; GENETICS; METABOLISM; MUSCLE ATROPHY; MUSCLE HYPOTONIA; MUTATION; X LINKED MENTAL RETARDATION; XENOPUS;

ANIMALS; CELL MEMBRANE; CYSTEINE PROTEINASE INHIBITORS; DIMETHYL SULFOXIDE; DOGS; GENISTEIN; IODINE RADIOISOTOPES; LEUPEPTINS; MADIN DARBY CANINE KIDNEY CELLS; MENTAL RETARDATION, X-LINKED; MICROSCOPY, CONFOCAL; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE HYPOTONIA; MUSCULAR ATROPHY; MUTATION; OOCYTES; PHENYLBUTYRATES; PROTEIN TRANSPORT; THYROXINE; TRIIODOTHYRONINE; XENOPUS;

EID: 84948129770     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1393     Document Type: Article

References (46)

1. Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. 2004;364:1435-1437.
2. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 2004;74:168-175.
3. Allan W, Herndon CN, Dudley FC. Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly. Am J Ment Defic. 1944;48:325-334.
4. Schwartz CE, May MM, Carpenter NJ, et al. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet. 2005;77:41-53.
5. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem. 2003;278:40128-40135.
6. Kinne A, Kleinau G, Hoefig CS, et al. Essential molecular determinants for thyroid hormone transport and first structural implications for monocarboxylate transporter 8. J Biol Chem. 2010;285: 28054-28063.
7. Jansen J, Friesema EC, Kester MH, et al. Functional analysis of monocarboxylate transporter 8 mutations identified in patients with X-linked psychomotor retardation and elevated serum triiodothyronine. J Clin Endocrinol Metab. 2007;92:2378-2381.
8. Kinne A, Roth S, Biebermann H, Köhrle J, Grüters A, Schweizer U. Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type dependent. J Mol Endocrinol. 2009; 43:263-271.
9. Friesema EC, Visser WE, Visser TJ. Genetics and phenomics of thyroid hormone transport by MCT8. Mol Cell Endocrinol. 2010;322: 107-113.
10. Kersseboom S, Kremers GJ, Friesema EC, et al. Mutations inMCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution. Mol Endocrinol. 2013;27:801-813.
11. Heuer H, Maier MK, Iden S, et al. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology. 2005;146:1701-1706.
12. Wirth EK, Roth S, Blechschmidt C, et al. Neuronal 3', 3, 5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci. 2009;29:9439-9449.
13. Braun D, Kinne A, Brauer AU, et al. Developmental and cell typespecific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia. 2011;59:463-471.
14. Alkemade A, Friesema EC, Unmehopa UA, et al. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus. J Clin Endocrinol Metab. 2005;90:4322-4334.
15. Roberts LM, Woodford K, Zhou M, et al. Expression of the thyroid hormone transportersMCT8(SLC16A2) andOATP14(SLCO1C1) at the blood-brain barrier. Endocrinology. 2008;149:6251-6261.
16. Lopez-Espindola D, Morales-Bastos C, Grijota-Martinez C, et al. Mutations of the thyroid hormone transporter MCT8 cause prenatal brain damage and persistent hypomyelination. J Clin Endocrinol Metab. 2014;99:E2799-E2804.
17. Mayerl S, Müller J, Bauer R, et al. Transporters MCT8 and OATP1C1 maintain murine brain thyroid hormone homeostasis. J Clin Invest. 2014;124:1987-1999.
18. Schweizer U, Köhrle J. Function of thyroid hormone transporters in the central nervous system. Biochim Biophys Acta. 2013;1830: 3965-3973.
19. Visser WE, Jansen J, Friesema EC, et al. Novel pathogenic mechanism suggested by ex vivo analysis of MCT8 (SLC16A2) mutations. Hum Mutat. 2009;30:29-38.
20. Verge CF, Konrad D, Cohen M, et al. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. J Clin Endocrinol Metab. 2012;97:4515-4523.
21. Horn S, Kersseboom S, Mayerl S, et al. Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter mct8. Endocrinology. 2013;154: 968-979.
22. Kersseboom S, Horn S, Visser WE, et al. In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol Endocrinol. 2014;28:1961-1970.
23. Ferrara AM, Liao XH, Gil-Ibanez P, et al. Placenta passage of the thyroid hormone analog DITPA to male wild-type and Mct8-deficient mice. Endocrinology. 2014;155:4088-4093.
24. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323-355.
25. Bernier V, Lagace M, Bichet DG, Bouvier M.Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab. 2004;15:222-228.
26. Özcan U, Yilmaz E, Özcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140.
27. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629-9634.
28. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones. 1996;1:117-125.
29. Gelman MS, Kopito RR. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. J Clin Invest. 2002; 110:1591-1597.
30. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508- CFTR. J Clin Invest. 1997;100:2457-2465.
31. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.AmJ Respir Crit Care Med. 1998;157:484-490.
32. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011;11:227-249.
33. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. Proc Natl Acad Sci USA. 2000; 97:1796-1801.
34. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220-231.
35. Braun D, Lelios I, Krause G, Schweizer U. Histidines in potential substrate recognition sites affect thyroid hormone transport by monocarboxylate transporter 8 (MCT8). Endocrinology. 2013; 154:2553-2561.
36. Braun D, Kim TD, le Coutre P, Köhrle J, Hershman JM, Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab. 2012;97: E100-E105.
37. Groeneweg S, Friesema EC, Kersseboom S, et al. The role of Arg445 and Asp498 in the human thyroid hormone transporter MCT8. Endocrinology. 2014;155:618-626.
38. Renko K, Schache S, Hoefig CS, et al. An improved nonradioactive screening method identifies genistein and xanthohumol as potent inhibitors of iodothyronine deiodinases. Thyroid. 2015;25:962-968.
39. Di Cosmo C, Liao XH, Dumitrescu AM, Philp NJ, Weiss RE, Refetoff S. Mice deficient inMCT8reveal a mechanism regulating thyroid hormone secretion. J Clin Invest. 2010;120:3377-3388.
40. Wirth EK, Sheu SY, Chiu-Ugalde J, et al. Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy. Eur J Endocrinol. 2011;165:555-561.
41. Wemeau JL, Pigeyre M, Proust-Lemoine E, et al. Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8. J Clin Endocrinol Metab. 2008;93:2084-2088.
42. Di Cosmo C, Liao XH, Dumitrescu AM, Weiss RE, Refetoff S. A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology. 2009; 150:4450-4458.
43. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508- CFTR. Am J Physiol Cell Physiol. 2000;278:C259-C267.
44. Ingolfsson HI, Thakur P, Herold KF, et al. Phytochemicals perturb membranes and promiscuously alter protein function. ACS Chem Biol. 2014;9:1788-1798.
45. Radovic B, Mentrup B, Köhrle J. Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. Br J Nutr. 2006;95:1171-1176.
46. Marini H, Polito F, Adamo EB, Bitto A, Squadrito F, Benvenga S. Update on genistein and thyroid: an overall message of safety. Front Endocrinol. 2012;3:94.